Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Orchard Therapeutics stock price, quote, forecast and news

ORTX
US68570P1012
A2N8KD

Price

16.70
Today +/-
+0
Today %
+0 %
P

Orchard Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Orchard Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Orchard Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Orchard Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Orchard Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Orchard Therapeutics Stock Price History

DateOrchard Therapeutics Price
2/2/202416.70 undefined
2/1/202416.70 undefined

Orchard Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Orchard Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Orchard Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Orchard Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Orchard Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Orchard Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Orchard Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Orchard Therapeutics’s growth potential.

Orchard Therapeutics Revenue, EBIT and net profit per share

DateOrchard Therapeutics RevenueOrchard Therapeutics EBITOrchard Therapeutics Net Income
2028e118.52 M undefined-78.85 M undefined-90.37 M undefined
2027e200.8 M undefined-34.42 M undefined3.87 M undefined
2026e155.24 M undefined-51.3 M undefined-16.78 M undefined
2025e98.86 M undefined-75.87 M undefined-40.02 M undefined
2024e56.64 M undefined-115.75 M undefined-348.58 M undefined
2023e28.1 M undefined-105.23 M undefined-373.11 M undefined
202222.66 M undefined-125.31 M undefined-150.66 M undefined
20211.68 M undefined-140.43 M undefined-144.58 M undefined
20202.6 M undefined-153.23 M undefined-151.98 M undefined
20192.51 M undefined-172.87 M undefined-163.42 M undefined
20182.08 M undefined-235.03 M undefined-230.5 M undefined
20170 undefined-38.51 M undefined-39.74 M undefined
20160 undefined-19.2 M undefined-19.09 M undefined

Orchard Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20162017201820192020202120222023e2024e2025e2026e2027e2028e
00222122285698155200118
------50.002,100.0027.27100.0075.0058.1629.03-41.00
--50.0050.0050.00100.0068.18------
00111115000000
-19-38-235-172-153-140-125-105-115-75-51-34-78
---11,750.00-8,600.00-7,650.00-14,000.00-568.18-375.00-205.36-76.53-32.90-17.00-66.10
-19-39-230-163-151-144-150-373-348-40-163-90
-105.26489.74-29.13-7.36-4.644.17148.67-6.70-88.51-60.00-118.75-3,100.00
8.318.318.599.329.94123.96127.98000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Orchard Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Orchard Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2016201720182019202020212022
3.589.9335.8325191.9220.1143.8
01.22.21.40.91.58.5
0210.51520.135.28.8
00000.723.4
0.41.26.98.59.916.53.7
3.994.3355.4349.9223.5275.3168.2
0.22.75.52734.629.130.9
0000000
0.10.4013.7000
000005.63.6
0000000
0058.722.812.516.3
0.33.110.549.457.447.250.8
4.297.4365.9399.3280.9322.5219
17134.110.912.312.516.316.4
3.47.6587.5738.5771.2940.7956.7
-19.7-59.4-290.2-453.7-605.6-750.2-900.9
-0.34.13.220.43.226
0000000
0.486.4311.4299.1178.521098.2
0.73.918.1128.8109.3
1.74.624.140.9373137.2
1.42.35.730.914.6
0000000
00004.90.89.4
3.810.847.955.951.642.860.5
00024.720.232.123
0000000
00.16.819.530.737.637.1
00.16.844.250.969.760.1
3.810.954.7100.1102.5112.5120.6
4.297.3366.1399.2281322.5218.8
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Orchard Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Orchard Therapeutics's financial health and stability.

Assets

Orchard Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Orchard Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Orchard Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Orchard Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (k)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (k)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2016201720182019202020212022
-19-39-230-163-151-144-150
0011222
0000-2,0001,000-3,000
1236-17-3-1736
3510232575555
0001122
0001,0001,0001,0000
-14-32-97-166-126-125-75
0-1-4-4-2-2-6
0-1-4-309157-3290
000-304160-2997
0000000
00024070
1811535413331570
1811535415731580
------6.00-
0000000
286249-31636012
-14.76-34.05-101.57-170.5-128.94-127.45-82.5
0000000

Orchard Therapeutics stock margins

The Orchard Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Orchard Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Orchard Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Orchard Therapeutics's sales revenue. A higher gross margin percentage indicates that the Orchard Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Orchard Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Orchard Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Orchard Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Orchard Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Orchard Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Orchard Therapeutics Margin History

Orchard Therapeutics Gross marginOrchard Therapeutics Profit marginOrchard Therapeutics EBIT marginOrchard Therapeutics Profit margin
2028e70.08 %-66.53 %-76.25 %
2027e70.08 %-17.14 %1.93 %
2026e70.08 %-33.05 %-10.81 %
2025e70.08 %-76.75 %-40.49 %
2024e70.08 %-204.36 %-615.43 %
2023e70.08 %-374.52 %-1,327.89 %
202270.08 %-553 %-664.87 %
202186.31 %-8,358.93 %-8,605.95 %
202066.92 %-5,893.46 %-5,845.38 %
201968.13 %-6,887.25 %-6,510.76 %
201879.33 %-11,299.52 %-11,081.73 %
201770.08 %0 %0 %
201670.08 %0 %0 %

Orchard Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Orchard Therapeutics earnings per share therefore indicates how much revenue Orchard Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Orchard Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Orchard Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Orchard Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Orchard Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Orchard Therapeutics Revenue, EBIT and net profit per share

DateOrchard Therapeutics Sales per ShareOrchard Therapeutics EBIT per shareOrchard Therapeutics Earnings per Share
2028e0.94 undefined0 undefined-0.71 undefined
2027e1.59 undefined0 undefined0.03 undefined
2026e1.23 undefined0 undefined-0.13 undefined
2025e0.78 undefined0 undefined-0.32 undefined
2024e0.45 undefined0 undefined-2.75 undefined
2023e0.22 undefined0 undefined-2.95 undefined
20220.18 undefined-0.98 undefined-1.18 undefined
20210.01 undefined-1.13 undefined-1.17 undefined
20200.26 undefined-15.42 undefined-15.29 undefined
20190.27 undefined-18.55 undefined-17.53 undefined
20180.24 undefined-27.36 undefined-26.83 undefined
20170 undefined-4.63 undefined-4.78 undefined
20160 undefined-2.31 undefined-2.3 undefined

Orchard Therapeutics business model

Orchard Therapeutics PLC is a biopharmaceutical company based in London. It was founded in 2015 and is traded on the NASDAQ and the London Stock Exchange. The company focuses on the development and commercialization of gene therapy products for rare and life-threatening diseases for which there is currently no cure. Orchard Therapeutics has its roots in the research and development of gene therapy products at the University College London (UCL) and the Great Ormond Street Hospital for Children (GOSH). The company has a strong partnership with these institutions and utilizes their resources for the development of new therapies. This close collaboration allows Orchard Therapeutics to focus on the research and development of gene therapy products for rare diseases. The business model of Orchard Therapeutics is to develop gene therapies for rare diseases that currently have no treatment options. These products are then licensed to pharmaceutical companies that are responsible for the production and marketing of the products. Orchard Therapeutics then receives a licensing fee and potential milestone payments for the sale of the products. Orchard Therapeutics has various divisions specializing in the development of gene therapies for different diseases. For example, the hemophilia division develops gene therapies for people with hemophilia, a genetic disease that impairs blood clotting. Other divisions focus on the development of gene therapies for muscular dystrophy, B-cell immunodeficiency, and chronic granulomatosis. The company has a broad portfolio of products currently in development. One of the most well-known products is "OTL-101," a gene therapy for the treatment of adenosine deaminase deficiency immunodeficiency (ADA-SCID), a severe type of immunodeficiency that can lead to infections and serious illness. Another important gene therapy is "OTL-103," which is used for the treatment of Wiskott-Aldrich syndrome (WAS), a rare genetic disorder that affects the immune system. Orchard Therapeutics manages to develop gene therapies for rare diseases by using a unique technology platform. This platform includes the use of lentiviruses that can insert genetic information into cells of the body. The gene therapies developed on this platform can help replace defective or missing genes with functional genes to treat diseases. Overall, Orchard Therapeutics is an emerging biotechnology company that focuses on the development of gene therapy products for rare and life-threatening diseases. The company has a strong partnership with leading medical institutions and utilizes a unique technology platform to develop gene therapies. With a wide range of products in development and potential groundbreaking therapies in the pipeline, Orchard Therapeutics is expected to play a significant role in the development of gene therapies for rare diseases. Orchard Therapeutics is one of the most popular companies on Eulerpool.com.

Orchard Therapeutics SWOT Analysis

Strengths

Orchard Therapeutics PLC is a leading biopharmaceutical company that specializes in gene therapies. The company's main strengths include:

  • Pioneering technology: Orchard Therapeutics employs state-of-the-art gene therapy techniques, allowing them to develop innovative treatments for rare diseases.
  • Strong research and development capabilities: The company has a robust R&D pipeline focused on addressing unmet medical needs and bringing transformative therapies to patients.
  • Strategic partnerships: Orchard Therapeutics has established strategic collaborations with academic institutions, research organizations, and pharmaceutical companies, enhancing their expertise and enabling access to valuable resources and knowledge.
  • Experienced management team: The company is led by a team of highly experienced professionals with a proven track record in the biopharmaceutical industry.

Weaknesses

While Orchard Therapeutics has numerous strengths, it also faces certain weaknesses that could impact its performance:

  • Limited product portfolio: As a gene therapy-focused company, Orchard Therapeutics currently has a relatively small product portfolio, which may increase its dependency on the success of a few key therapies.
  • Regulatory challenges: The development and commercialization of gene therapies face complex regulatory requirements, which could result in delays or obstacles in obtaining approvals.
  • High development costs: Gene therapy development is costly and time-consuming. Orchard Therapeutics may face financial challenges in funding its R&D activities and scaling up production.

Opportunities

Orchard Therapeutics has several opportunities to capitalize on in the biopharmaceutical market:

  • Increasing demand for gene therapies: The growing prevalence of rare diseases and the potential of gene therapies offer a significant opportunity for Orchard Therapeutics to address unmet medical needs.
  • Expanding market presence: By further developing their gene therapies and successfully commercializing their products, Orchard Therapeutics can expand its market presence and potentially capture significant market share.
  • Advancements in technology: Continued advancements in gene therapy technologies provide opportunities for Orchard Therapeutics to improve treatment efficacy, safety, and scalability.

Threats

Orchard Therapeutics should also be aware of potential threats that might pose challenges to its success:

  • Intense competition: The field of gene therapy is highly competitive, with numerous companies investing in the development of similar treatments. Orchards Therapeutics needs to differentiate itself to maintain a competitive edge.
  • Intellectual property risks: Intellectual property and patent rights are crucial in the field of gene therapies. Orchard Therapeutics may face legal challenges or loss of exclusivity if their intellectual property is infringed upon.
  • Market access and reimbursement: Reimbursement challenges and pricing pressures may affect the adoption and availability of Orchard Therapeutics' gene therapies in different healthcare systems.

Orchard Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Orchard Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Orchard Therapeutics shares outstanding

The number of shares was Orchard Therapeutics in 2023 — This indicates how many shares 127.98 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Orchard Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Orchard Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Orchard Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Orchard Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Orchard Therapeutics Stock splits

In Orchard Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Orchard Therapeutics.

Orchard Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2023-0.77 -1.5  (-96.08 %)2023 Q3
6/30/2023-1.42 -0.7  (50.75 %)2023 Q2
3/31/2023-1.7 -1.2  (29.34 %)2023 Q1
12/31/2022-2.16 -0.6  (72.21 %)2022 Q4
9/30/2022-2.43 -3.7  (-52.05 %)2022 Q3
6/30/2022-2.64 -4  (-51.27 %)2022 Q2
3/31/2022-2.67 -3.2  (-20 %)2022 Q1
12/31/2021-2.85 -2.9  (-1.58 %)2021 Q4
9/30/2021-0.26 -0.29  (-12.23 %)2021 Q3
6/30/2021-0.33 -0.29  (12.78 %)2021 Q2
1
2

Orchard Therapeutics list of shareholders

%
Name
Stocks
Change
Date
1.61 % Deep Track Capital LP2,041,670875,0006/30/2023
1.07 % Beryl Capital Management, LLC1,350,0001,350,00010/5/2023
0.98 % Glaxo Group, Ltd.1,245,5251,245,5253/31/2023
0.73 % Magides (Richard)918,661609,02012/31/2022
0.60 % Cowen Investment Management LLC755,738-30,0006/30/2023
0.54 % Zentree Investment Management Pte Ltd677,395339,28912/31/2022
0.40 % Federated Hermes Global Investment Management Corp.508,222-1,417,1556/30/2023
0.28 % Temasek Holdings Pte. Ltd.352,379-79,5256/30/2023
0.25 % Deerfield Management Company, L.P.316,16906/30/2023
0.20 % Platinum Asset Management248,462129,3346/30/2023
1
2
3
4
5
...
10

Orchard Therapeutics Executives and Management Board

Mr. Bobby Gaspar58
Orchard Therapeutics Chief Executive Officer, Director (since 2016)
Compensation 4.35 M
Mr. Frank Thomas52
Orchard Therapeutics President, Chief Operating Officer
Compensation 1.97 M
Mr. James Geraghty67
Orchard Therapeutics Non-Executive Independent Chairman of the Board (since 2018)
Compensation 216,592
Mr. Charles Rowland63
Orchard Therapeutics Non-Executive Independent Director
Compensation 199,592
Ms. Alicia Secor59
Orchard Therapeutics Non-Executive Independent Director
Compensation 193,592
1
2

Orchard Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Oxford BioMedica Stock
Oxford BioMedica
SupplierCustomer0,680,880,950,940,70-
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer0,500,72-0,70-0,58-0,78-0,75
CryoPort Stock
CryoPort
SupplierCustomer0,370,480,920,910,630,25
bluebird bio Stock
bluebird bio
SupplierCustomer-0,010,620,920,950,930,71
Gen Ilac Sag Ur Stock
Gen Ilac Sag Ur
SupplierCustomer-0,63-0,46-0,90-0,65--
1

Most common questions regarding Orchard Therapeutics

What values and corporate philosophy does Orchard Therapeutics represent?

Orchard Therapeutics PLC represents values of innovation, collaboration, and patient-focused care. Their corporate philosophy is centered around developing transformative gene therapies for rare diseases. With a commitment to advancing precision medicine, Orchard Therapeutics PLC aims to improve the lives of patients through the development and commercialization of innovative treatments. Their dedicated team of experts, cutting-edge research, and strategic partnerships drive their mission to address critical unmet medical needs. Orchard Therapeutics PLC is dedicated to delivering hope and long-term solutions to patients and their families, making a positive impact on the healthcare industry.

In which countries and regions is Orchard Therapeutics primarily present?

Orchard Therapeutics PLC is primarily present in several countries and regions. The company's presence extends to the United States, the United Kingdom, and the European Union. With its headquarters in London, Orchard Therapeutics PLC has established a strong global footprint within the pharmaceutical industry. By focusing on gene therapies and developing innovative treatment options, Orchard Therapeutics PLC offers hope to patients worldwide. As a trusted name in the field, Orchard Therapeutics PLC continues to expand its reach and impact, striving to improve the lives of individuals affected by serious rare diseases.

What significant milestones has the company Orchard Therapeutics achieved?

Orchard Therapeutics PLC has achieved several significant milestones. Firstly, the company successfully completed its initial public offering (IPO) on October 31, 2018, raising approximately $200 million. This allowed Orchard Therapeutics to expand its operations and further progress its pipeline of innovative gene therapies. Additionally, the company obtained Breakthrough Therapy Designation from the U.S. FDA for its ex vivo autologous hematopoietic stem cell gene therapy in 2018. Orchard Therapeutics also initiated multiple clinical trials for various rare diseases, demonstrating the efficacy and safety of their therapies. Moreover, the company has entered strategic collaborations with renowned organizations like GSK and UCLA for further advancements in its gene therapy research and development. Orchard Therapeutics PLC continues to achieve remarkable milestones on its mission to transform the lives of patients with serious genetic diseases.

What is the history and background of the company Orchard Therapeutics?

Orchard Therapeutics PLC is a renowned biopharmaceutical company specializing in gene therapies for rare diseases. Founded in 2015, Orchard Therapeutics focuses on developing innovative treatments using ex-vivo autologous hematopoietic stem cell gene therapy. With a mission to transform the lives of patients with severe genetic disorders, Orchard Therapeutics aims to provide long-lasting and potentially curative solutions. The company has a comprehensive portfolio of therapies in different stages of development, targeting disorders like inherited immunodeficiencies, metabolic disorders, and more. Orchard Therapeutics brings together cutting-edge science, experienced professionals, and strategic collaborations to drive advancements in the field of gene therapy and improve outcomes for patients worldwide.

Who are the main competitors of Orchard Therapeutics in the market?

The main competitors of Orchard Therapeutics PLC in the market include bluebird bio, CRISPR Therapeutics, and Novartis AG.

In which industries is Orchard Therapeutics primarily active?

Orchard Therapeutics PLC primarily operates in the biotechnology and pharmaceutical industries.

What is the business model of Orchard Therapeutics?

The business model of Orchard Therapeutics PLC focuses on developing and commercializing gene therapies for the treatment of rare genetic diseases. The company utilizes ex-vivo gene therapy approaches, where a patient's own cells are genetically modified outside the body and then infused back into the patient. By leveraging this innovative technology, Orchard Therapeutics aims to provide long-term, potentially curative therapies to patients suffering from debilitating genetic disorders. With a strong emphasis on research and development, the company strives to address unmet medical needs and improve the lives of patients with rare diseases worldwide.

What is the P/E ratio of Orchard Therapeutics 2024?

The Orchard Therapeutics P/E ratio is -6.13.

What is the P/S ratio of Orchard Therapeutics 2024?

The Orchard Therapeutics P/S ratio is 37.73.

What is the AlleAktien quality score of Orchard Therapeutics?

The AlleAktien quality score for Orchard Therapeutics is 3/10.

What is the revenue of Orchard Therapeutics 2024?

The expected Orchard Therapeutics revenue is 56.64 M USD.

How high is the profit of Orchard Therapeutics 2024?

The expected Orchard Therapeutics profit is -348.58 M USD.

What is the business model of Orchard Therapeutics

Orchard Therapeutics PLC is a biopharmaceutical company based in the UK that specializes in the development and commercialization of gene therapies for rare diseases. The company utilizes a technology known as ex-vivo gene therapy, where the target gene is modified in the laboratory and then administered to the patients. The company operates in two business segments: research and development, and product commercialization. Orchard Therapeutics focuses on rare immunodeficiency diseases and utilizes their ex-vivo gene therapy technology to treat a variety of genetic diseases. In the research and development field, the company works on developing new gene therapy products for various rare diseases. This includes identifying target genes as well as developing the gene therapy itself. Orchard Therapeutics evaluates both their own technologies and technologies from partners. Currently, Orchard Therapeutics offers a gene therapy product called Strimvelis, which is used to treat ADA-SCID, a rare form of immunodeficiency. Strimvelis is the first gene therapy to receive conditional approval from the European Union. Additionally, the company plans to develop more gene therapy products for rare diseases. Orchard Therapeutics has already initiated clinical trials for their gene therapy products for Wiskott-Aldrich syndrome, metachromatic leukodystrophy, and X-linked adrenoleukodystrophy. Orchard Therapeutics works closely with regulatory authorities to ensure that their gene therapy products meet the highest standards of safety and efficacy. The company markets its products directly or through distribution partners to patients affected by rare diseases. To meet the demand for gene therapy products for rare diseases, the company has acquired a manufacturing facility for gene therapy products in California, USA. Orchard Therapeutics has also formed partnerships with other biotech companies to further develop their technology and products. The collaboration with GSK to develop a gene therapy for adrenoleukodystrophy has the potential to expand Orchard Therapeutics' portfolio. Overall, Orchard Therapeutics has a promising future in the gene therapy industry. With their ex-vivo gene therapy technology and ability to develop gene therapy products for a variety of rare diseases, the company is well positioned to improve the lives of patients with rare diseases.

What is the Orchard Therapeutics dividend?

Orchard Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Orchard Therapeutics pay dividends?

The dividend cannot currently be calculated for Orchard Therapeutics or the company does not pay out a dividend.

What is the Orchard Therapeutics ISIN?

The ISIN of Orchard Therapeutics is US68570P1012.

What is the Orchard Therapeutics WKN?

The WKN of Orchard Therapeutics is A2N8KD.

What is the Orchard Therapeutics ticker?

The ticker of Orchard Therapeutics is ORTX.

How much dividend does Orchard Therapeutics pay?

Over the past 12 months, Orchard Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Orchard Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Orchard Therapeutics?

The current dividend yield of Orchard Therapeutics is .

When does Orchard Therapeutics pay dividends?

Orchard Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Orchard Therapeutics?

Orchard Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Orchard Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Orchard Therapeutics located?

Orchard Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Orchard Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Orchard Therapeutics from 8/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/30/2024.

When did Orchard Therapeutics pay the last dividend?

The last dividend was paid out on 8/30/2024.

What was the dividend of Orchard Therapeutics in the year 2023?

In the year 2023, Orchard Therapeutics distributed 0 USD as dividends.

In which currency does Orchard Therapeutics pay out the dividend?

The dividends of Orchard Therapeutics are distributed in USD.

All fundamentals about Orchard Therapeutics

Our stock analysis for Orchard Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orchard Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.